BioNTech Historical Income Statement

0A3M Stock

USD 123.45 0.55 0.44%

Historical analysis of BioNTech income statement accounts such as Other Operating Expenses of 385.3 M, EBIT of 14.4 B or Net Income Applicable To Common Shares of 12.4 B can show how well BioNTech SE performed in making a profits. Evaluating BioNTech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioNTech's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining BioNTech SE latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioNTech SE is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About BioNTech Income Statement Analysis

BioNTech SE Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioNTech shareholders. The income statement also shows BioNTech investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

BioNTech Income Statement Chart

At this time, BioNTech's Net Interest Income is quite stable compared to the past year. Interest Income is expected to rise to about 431.8 M this year, although the value of Operating Income will most likely fall to about 987.8 M.

Other Operating Expenses Selling General Administrative Total Revenue Gross Profit

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioNTech SE. It is also known as BioNTech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Revenue

Total revenue comprises all receipts BioNTech SE generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of BioNTech SE minus its cost of goods sold. It is profit before BioNTech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from BioNTech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Gross Profit	12.8B	3.2B	3.7B	5.8B
Total Revenue	17.3B	3.8B	4.4B	7.5B

Gross Profit Total Revenue

BioNTech income statement Correlations

	Other Operating Expenses	Ebit	Income Tax Expense	Tax Provision	Net Interest Income	Interest Income	Selling General Administrative	Total Revenue	Gross Profit	Operating Income	Net Income From Continuing Ops	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income
Other Operating Expenses		0.89	0.93	0.3	0.99	0.99	0.99	0.55	0.55	0.32	0.37	0.98	0.9	0.45	0.81	0.98	0.35	0.21	0.37
Ebit	0.89		0.99	0.63	0.8	0.82	0.95	0.8	0.81	0.63	0.66	0.92	1.0	0.69	0.94	0.89	0.65	0.28	0.66
Income Tax Expense	0.93	0.99		0.57	0.86	0.88	0.97	0.76	0.77	0.58	0.61	0.95	1.0	0.65	0.93	0.93	0.6	0.27	0.61
Tax Provision	0.3	0.63	0.57		0.13	0.17	0.41	0.96	0.96	1.0	0.99	0.33	0.61	0.96	0.78	0.22	1.0	0.73	0.99
Net Interest Income	0.99	0.8	0.86	0.13		1.0	0.94	0.4	0.4	0.17	0.22	0.95	0.82	0.31	0.7	0.96	0.19	0.13	0.22
Interest Income	0.99	0.82	0.88	0.17	1.0		0.96	0.44	0.44	0.21	0.25	0.96	0.84	0.35	0.73	0.97	0.23	0.15	0.25
Selling General Administrative	0.99	0.95	0.97	0.41	0.94	0.96		0.64	0.65	0.43	0.47	0.99	0.96	0.54	0.87	0.98	0.45	0.22	0.47
Total Revenue	0.55	0.8	0.76	0.96	0.4	0.44	0.64		1.0	0.96	0.97	0.58	0.79	0.97	0.9	0.48	0.97	0.7	0.97
Gross Profit	0.55	0.81	0.77	0.96	0.4	0.44	0.65	1.0		0.96	0.97	0.59	0.8	0.96	0.9	0.49	0.97	0.67	0.97
Operating Income	0.32	0.63	0.58	1.0	0.17	0.21	0.43	0.96	0.96		1.0	0.36	0.61	0.98	0.8	0.24	1.0	0.77	1.0
Net Income From Continuing Ops	0.37	0.66	0.61	0.99	0.22	0.25	0.47	0.97	0.97	1.0		0.4	0.64	0.99	0.82	0.28	1.0	0.78	1.0
Research Development	0.98	0.92	0.95	0.33	0.95	0.96	0.99	0.58	0.59	0.36	0.4		0.93	0.46	0.83	0.99	0.38	0.14	0.4
Ebitda	0.9	1.0	1.0	0.61	0.82	0.84	0.96	0.79	0.8	0.61	0.64	0.93		0.67	0.94	0.9	0.63	0.28	0.64
Cost Of Revenue	0.45	0.69	0.65	0.96	0.31	0.35	0.54	0.97	0.96	0.98	0.99	0.46	0.67		0.86	0.35	0.98	0.83	0.99
Total Operating Expenses	0.81	0.94	0.93	0.78	0.7	0.73	0.87	0.9	0.9	0.8	0.82	0.83	0.94	0.86		0.76	0.81	0.54	0.82
Reconciled Depreciation	0.98	0.89	0.93	0.22	0.96	0.97	0.98	0.48	0.49	0.24	0.28	0.99	0.9	0.35	0.76		0.26	0.02	0.28
Income Before Tax	0.35	0.65	0.6	1.0	0.19	0.23	0.45	0.97	0.97	1.0	1.0	0.38	0.63	0.98	0.81	0.26		0.77	1.0
Total Other Income Expense Net	0.21	0.28	0.27	0.73	0.13	0.15	0.22	0.7	0.67	0.77	0.78	0.14	0.28	0.83	0.54	0.02	0.77		0.78
Net Income	0.37	0.66	0.61	0.99	0.22	0.25	0.47	0.97	0.97	1.0	1.0	0.4	0.64	0.99	0.82	0.28	1.0	0.78

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

High Positive Relationship

Ebitda	+ 1.0	Ebit
Ebitda	+ 1.0	Income Tax Expense
Operating Income	+ 1.0	Tax Provision
Income Before Tax	+ 1.0	Tax Provision
Interest Income	+ 1.0	Net Interest Income
Gross Profit	+ 1.0	Total Revenue

High Negative Relationship

Not Found

BioNTech income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	2.0M	5.4M	18.9M	3.9M	4.5M	5.3M
Other Operating Expenses	2.5M	9.1M	81.7M	319.1M	367.0M	385.3M
Ebit	(181.5M)	(325.8M)	14.7B	11.9B	13.7B	14.4B
Net Income Applicable To Common Shares	(48.0M)	(179.1M)	15.2M	10.3B	11.8B	12.4B
Income Tax Expense	600K	(200K)	(161M)	4.8B	5.5B	5.7B
Tax Provision	(161M)	4.8B	3.5B	255.8M	294.2M	279.5M
Net Interest Income	(3.5M)	(25.8M)	311.4M	349.7M	402.2M	422.3M
Interest Income	1.6M	1.5M	330.3M	357.6M	411.2M	431.8M
Selling General Administrative	101.4M	328.9M	544.2M	557.7M	641.4M	673.4M
Total Revenue	482.3M	19.0B	17.3B	3.8B	4.4B	7.5B
Gross Profit	423.0M	15.1B	12.8B	3.2B	3.7B	5.8B
Operating Income	(89.4M)	14.9B	12.6B	904.2M	1.0B	987.8M
Net Income From Continuing Ops	15.2M	10.3B	9.4B	930.3M	1.1B	1.0B
Research Development	647.1M	936.8M	1.5B	1.8B	2.1B	2.2B
Ebitda	(143.8M)	(105.1M)	15.1B	13.1B	15.1B	15.8B
Cost Of Revenue	59.3M	3.9B	4.5B	599.8M	689.8M	655.3M
Total Operating Expenses	571.7M	4.1B	4.7B	2.9B	3.4B	2.3B
Reconciled Depreciation	38.7M	75.2M	123.3M	183.4M	210.9M	221.5M
Income Before Tax	(145.8M)	15.0B	13.0B	1.2B	1.4B	1.3B
Total Other Income Expense Net	(52.9M)	156.3M	623.7M	(67.8M)	(78.0M)	(74.1M)
Net Income	15.2M	10.3B	9.4B	930.3M	1.1B	1.0B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:

How To Invest In BioNTech

Details

Is BioNTech Stock a good investment?

Details

What is BioNTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Historical Income Statement

About BioNTech Income Statement Analysis

BioNTech Income Statement Chart

Other Operating Expenses

Total Revenue

Gross Profit

BioNTech income statement Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY